Answers are grounded in this paper and cite their sources.
This review demonstrates that neoantigen-driven cancer vaccines improve immune responses in cancers, suggesting advancements in personalized immunotherapy.
Neoantigen-driven cancer vaccines have emerged as a transformative approach in precision oncology, harnessing tumor-specific mutations to elicit robust, tailored immune responses. This review focuses on neoantigen identification, vaccine platforms, clinical applications, and challenges. Leveraging next-generation sequencing (NGS) and bioinformatics, vaccines target neoantigens in cancers like melanoma, pancreatic cancer, and non-small cell lung cancer (NSCLC). mRNA platforms and peptide-based vaccines have shown promising clinical outcomes, particularly when combined with immune checkpoint inhibitors. Challenges include prediction accuracy, production scalability, and tumor microenvironment immunosuppression. Future directions involve AI-driven tools, novel delivery systems, and cost-reduction strategies to enhance accessibility.
No takes yet. Share an insight, caveat, or question.
Nzereogu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: